Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.
about
Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based ImmunogensThermodynamic Signatures of the Antigen Binding Site of mAb 447–52D Targeting the Third Variable Region of HIV-1 gp120Indirect detection of an epitope-specific response to HIV-1 gp120 immunization in human subjectsAnti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypesResistance of Subtype C HIV-1 Strains to Anti-V3 Loop Antibodies.Comparative magnitude of cross-strain conservation of HIV variable loop neutralization epitopesCould vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.Receptor binding domain based HIV vaccines.Computational prediction of neutralization epitopes targeted by human anti-V3 HIV monoclonal antibodiesHIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humansThe use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120.Quantitative assessment of masking of neutralization epitopes in HIV-1.Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.Longitudinal HIV-1 gp120-C2V3C3 phylogenetic surveillance and tropism evolution in patients under HAART.
P2860
Q27658173-93B2BA45-D59E-4726-A438-62D01ACF1855Q27679559-E5FF9D3D-ABA9-47D8-8715-F00B3C6D62D6Q28743129-5FBB2C56-C2CE-4865-9CEF-B85B005B483FQ28752503-5DD49C91-831B-4484-BB50-F3A49B5867ACQ30416200-82E6EA00-381F-49C0-B144-B099DC3C858BQ30994182-C4D13081-B9AB-4F33-9C43-F02045B11815Q33723429-3C3E7579-B8A7-48F8-AE4B-BDD653D72752Q34017550-72E913E8-4B92-4612-A09A-217273D43678Q34204047-EDC4CA01-6CCA-4C44-990E-6B6DBB977B70Q35033862-D4A3FBFC-50AE-4F75-A859-53BECE8DFB94Q35108505-44729001-26DF-4EE5-966F-D82825EACBB3Q36252656-9B1EB069-A948-4774-9E08-4EAA06D9E74EQ37462829-7D832FFA-1A16-4361-A1E3-53334997256CQ41909663-8DD9964B-472B-48F8-A0E0-B0829E3C13EAQ42204816-20C8083F-E29A-40FA-8628-FF0473B2A015Q44592371-E4542AA4-BEB0-4F6D-BC37-59CBA90C3BC2
P2860
Worldwide distribution of HIV type 1 epitopes recognized by human anti-V3 monoclonal antibodies.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Worldwide distribution of HIV ...... anti-V3 monoclonal antibodies.
@ast
Worldwide distribution of HIV ...... anti-V3 monoclonal antibodies.
@en
type
label
Worldwide distribution of HIV ...... anti-V3 monoclonal antibodies.
@ast
Worldwide distribution of HIV ...... anti-V3 monoclonal antibodies.
@en
prefLabel
Worldwide distribution of HIV ...... anti-V3 monoclonal antibodies.
@ast
Worldwide distribution of HIV ...... anti-V3 monoclonal antibodies.
@en
P2093
P2860
P356
P1476
Worldwide distribution of HIV ...... anti-V3 monoclonal antibodies.
@en
P2093
Abraham Pinter
Arthur Nadas
Chavdar Krachmarov
David Almond
James Swetnam
Susan Zolla-Pazner
Timothy Cardozo
P2860
P304
P356
10.1089/AID.2008.0188
P577
2009-04-01T00:00:00Z